REFERENCES
  1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet . 2020;395:497-506.
  2. Anca PS, Toth P P, Kempler P, Rizzo M. Gender differences in the battle against COVID‐19: Impact of genetics, comorbidities, inflammation and lifestyle on differences in outcomes. Int J Clin Pract. 2021;75 (2):e13666.
  3. Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer.Lancet Oncol . 2009;10:589-597.
  4. Rüthrich MM, Giessen-Jung C, Borgmann S, et al. COVID-19 in cancer patients: clinical characteristics and outcome-an analysis of the LEOSS registry. Ann Hematol . 2021;100:383-393.
  5. Liu H, Chen S, Liu M, Nie H, Lu H. Comorbid chronic diseases are strongly correlated with disease severity among COVID-19 patients: a systematic review and meta-analysis. Aging Dis . 2020;11:668-678.
  6. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol . 2020;21:335-337.
  7. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med . 2020;382:1708-1720.
  8. Lacey B, Lewington S, Clarke R, et al. Age-specific association between blood pressure and vascular and non-vascular chronic diseases in 0· 5 million adults in China: a prospective cohort study.Lancet Glob Health . 2018;6:e641-e649.
  9. Oruç MA, Öz H, Öztürk O. Investigation of the disease process and drug combinations in patients with suspected/confirmed COVID‐19 using favipiravir. Int j Clin Pract . 2021;00:e14167.
  10. Yang J, Zheng YA, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis . 2020;94:91-95.
  11. Frater JL, Zini G, d’Onofrio G, Rogers HJ. COVID‐19 and the clinical hematology laboratory. Int J Lab Hematol . 2020;42:11-18.
  12. Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19.J Clin Virol . 2020;127:104370.
  13. Wang, L. C-reactive protein levels in the early stage of COVID-19.Med Mal Infect . 2020;50:332-334.
  14. Zhang L, Yan X, Fan Q, et al. D‐dimer levels on admission to predict in‐hospital mortality in patients with Covid‐19. J Thromb Haemost . 2020;18:1324-1329.
  15. Liu J, Liu Y, Xiang P, et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med . 2020;18:1-12.
  16. Azab B, Zaher M, Weiserbs KF, et al. Usefulness of neutrophil to lymphocyte ratio in predicting short-and long-term mortality after non–ST-elevation myocardial infarction. Am J Cardiol . 2010;106:470-476.
  17. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. (2013). The systemic inflammation-based neutrophil–lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol . 2013;88:218-230.
  18. Giede-Jeppe A, Bobinger T, Gerner ST, et al. Neutrophil-to-lymphocyte ratio is an independent predictor for in-hospital mortality in spontaneous intracerebral hemorrhage. Cerebrovasc Dis . 2017;44:26-34.
  19. Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect . 2020;81:e6-e12.
  20. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis . 2020;71:762-768.
  21. Liu H, Chen S, Liu M, Nie H, Lu H. Comorbid chronic diseases are strongly correlated with disease severity among COVID-19 patients: a systematic review and meta-analysis. Aging Dis . 2020;11:668-678.
  22. Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. (2020). Clinical characteristics and outcomes of cancer patients with COVID‐19. J Med Virol . 2020;92:2067-2073.
  23. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol . 2020;21:335-337.
  24. Bellan M, Patti G, Hayden E, et al. Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients. Sci Rep . 2020;10:1-10.
  25. Stroppa EM, Toscani I, Citterio C, et al. Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy). Future Oncol . 2020;16:1425-1432.
  26. Taneri PE, Gómez-Ochoa SA, Llanaj E, et al. Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. Eur J Epidemiol . 2020;35:763-773.
  27. Gómez-Pastora J, Weigand M, Kim J, et al. Hyperferritinemia in critically ill COVID-19 patients–Is ferritin the product of inflammation or a pathogenic mediator?. Clin Chim Acta . 2020;509:249-251.
  28. Shoenfeld Y. Corona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning.Autoimmun Rev . 2020;19:102538.
TABLE 1 Some demographic characteristics of the patients and their distribution based on chronic systemic disease status